10-Q: American Oncology Network Reports First Quarter 2024 Results, Revenue Up 20%

American Oncology Network (AON) saw a 20% increase in total revenue in the first quarter of 2024 compared to the same period last year, driven by growth in patient service revenue.

Summary

• American Oncology Network (AON) reported a 20% increase in total revenue for the first quarter of 2024, reaching $364.3 million, compared to $303.7 million in the first quarter of 2023.
• Patient service revenue, the primary driver, increased by 19.8% to $361.5 million, due to both increased revenue per encounter and a rise in patient encounters.
• The company experienced a net loss of $25 million, with $7.8 million attributable to Class A Common Stockholders.
• Operating expenses rose by 26.1% to $383.6 million, primarily due to a $76.4 million increase in cost of revenue, driven by higher drug and medical supply costs.
• General and administrative expenses increased by $4.6 million, influenced by revenue cycle costs, computer expenses, and increased costs associated with being a public company.
• Adjusted EBITDA was $1.96 million, a decrease from $4.05 million in the same period last year, impacted by increased operating costs and revenue cycle transformation costs.
• The company's cash and cash equivalents stood at $74.9 million as of March 31, 2024, with $30.1 million in short-term marketable securities.
• AON has $80.9 million in outstanding long-term debt and $1.0 million available under its PNC Line of Credit.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While revenue growth is strong, the company's net loss and declining profitability are concerning. The company is facing challenges in managing costs and is experiencing some growing pains as a public company. The sentiment is neutral to slightly negative due to the financial losses.

Positives

• AON experienced a significant 20% increase in total revenue, indicating strong growth in its operations.
• Patient service revenue saw a substantial 19.8% increase, driven by both higher revenue per encounter and increased patient volume.
• The company has a solid cash position with $74.9 million in cash and cash equivalents and $30.1 million in short-term marketable securities.
• Other revenue increased by 44.6% due to an increase in service arrangements and data contracts.

Negatives

• The company reported a net loss of $25 million for the quarter, indicating ongoing challenges with profitability.
• Operating expenses increased by 26.1%, outpacing revenue growth, primarily due to higher drug and medical supply costs.
• Adjusted EBITDA decreased by 51.6% year-over-year, reflecting increased operating costs and revenue cycle transformation costs.
• The company experienced a $1.6 million non-cash charge related to the fair value adjustment of warrant liabilities.

Risks

• The company's profitability is being impacted by rising operating expenses, particularly drug and medical supply costs.
• The company is experiencing increased costs associated with being a public company, including legal, accounting, and insurance fees.
• The company's revenue growth was constrained by implicit price concessions associated with a billing system transition.
• The company's debt obligations, including $80.9 million in long-term debt, could pose a risk if interest rates rise or if the company's financial performance deteriorates.
• The company's reliance on a single supplier for the majority of its pharmaceutical inventory creates a concentration risk.

Future Outlook

The company believes its position in the market and focus on elevating oncology care with affiliated providers bodes well for future growth. The company's proprietary technology platform supports this growth and enables the Network Practices to standardize and deliver consistent care at scale. The company believes that its model will support growth into new markets and allow it to continue to service more patients across the United States.

Management Comments

• AON preserves and elevates community oncology by helping its physicians navigate the complex healthcare landscape, providing them an efficient platform to work autonomously and thrive, and most importantly, improving the quality of patient care that is being delivered.
• Our mission is to provide high quality, cost effective cancer care close to where patients live and work.
• We believe the key to accessible and equitable healthcare lies in the strength of community healthcare practices and we are committed to closing the gap in cancer care to ensure every patient has access to the optimal, comprehensive care needed to help in their fight against cancer.

Industry Context

The company operates in the oncology healthcare sector, which is characterized by increasing demand for cancer care services. The company's focus on community-based oncology management aligns with the trend of providing care closer to patients' homes. The company's integrated technology platform and focus on value-based care are also in line with industry trends.

Comparison to Industry Standards

• AON's revenue growth of 20% is strong compared to the overall healthcare industry, which typically sees single-digit growth rates.
• However, the company's net loss and declining Adjusted EBITDA indicate that it is facing challenges in managing costs, which is a common issue in the healthcare sector, particularly with rising drug prices and labor costs.
• Compared to other oncology-focused companies, AON's emphasis on community-based care and integrated services is a differentiator, but its financial performance needs improvement to match industry leaders.
• Companies like McKesson and Cardinal Health, which are major players in pharmaceutical distribution, have much larger revenue bases but also face similar challenges in managing costs and profitability.
• Smaller, more specialized oncology companies may have higher growth rates but also face greater risks due to their limited scale and resources.

Related Party Transactions

• The company has operating leases for thirteen of the office facilities owned by employees of the company.
• The company purchases the majority of pharmaceuticals inventory from a subsidiary under common control of a Legacy AON Shareholder.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and declining profitability.
• Employees may be affected by the company's efforts to manage costs and improve efficiency.
• Patients may benefit from the company's focus on providing high-quality, cost-effective cancer care.
• Payors may benefit from the company's efforts to deliver care at a lower cost point.

Next Steps

• The company will continue to focus on expanding its operations and sales and marketing efforts.
• The company will continue to implement measures designed to improve its internal control over financial reporting to remediate material weaknesses.
• The company will continue to monitor and manage its operating costs, particularly drug and medical supply costs.
• The company will continue to evaluate and modify its preferred drug formulary through its Pharmacy and Therapeutics Committee.

Key Dates

Keywords

oncology, revenue, EBITDA, healthcare, pharmacy, patient care, financial results, medical, cancer treatment, clinical services